PureTech Health plc (PRTC) priced its founded entity Seaport Therapeutics’ Nasdaq IPO on April 30, 2026 at the top of its target range, raising gross proceeds of $254.9 million. The offering sold 14.16 million shares at $18.00 each, with an additional 2.124 million shares available under a 30‑day option for underwriters.
The IPO will be listed on the Nasdaq Global Select Market under the ticker “SPTX” and will begin trading on May 1, 2026, with the offering closing on May 4, 2026. Upon completion, PureTech will hold approximately 16.68 million shares of Seaport common stock, reducing its ownership stake from roughly 43% to about 33% while retaining significant upside through retained equity and royalty rights.
Seaport’s upsized offering and pricing at the top of its range reflect strong investor demand for its neuropsychiatry pipeline. The company’s proprietary Glyph platform, designed to improve oral bioavailability and reduce first‑pass metabolism, underpins its lead programs GlyphAllo™ (SPT‑300) for major depressive disorder and GlyphAgo™ (SPT‑320) for generalized anxiety disorder. The IPO proceeds will fund the advancement of these programs and other pipeline candidates, accelerating clinical development timelines in a capital‑intensive therapeutic area.
Prior to the IPO, Seaport had reported a net loss of $74.9 million in 2025, up from $46.9 million in 2024, indicating a widening loss profile as the company invests heavily in research and development. The IPO also follows two prior equity financings: a $100 million Series A in April 2024 and a $225 million Series B in October 2024, underscoring sustained investor confidence in the company’s technology and team.
PureTech’s hub‑and‑spoke model is exemplified by this transaction. By spinning out high‑valuation entities like Seaport, PureTech generates liquidity for the parent company while maintaining a strategic equity position. The $255 million raised provides Seaport with the capital needed to progress its pipeline, while PureTech benefits from the upside potential of a successful, later‑stage company that it continues to support through retained equity and royalty arrangements.
PureTech’s cash position remains robust, with $277.1 million in cash, cash equivalents, and short‑term investments at the end of 2025 and $248.1 million at March 31, 2026. The IPO proceeds will extend the company’s operational runway and support future growth initiatives across its portfolio of founded entities.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.